Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset
publication date: May 3, 2022
Shanghai Hansoh Pharma announced a $218 million agreement to acquire Greater China rights for a small molecule oncology candidate developed by NiKang Pharma of Delaware. NiKang is currently conducting a US Phase I/II dose escalation and expansion trial of NKT2152, a small molecule drug that inhibits HIF2α, in patients with clear cell renal cell carcinoma. Hansoh will pay $15 million upfront and up to $203 million in milestone payments, plus royalties. It’s the second partnership between the two companies: two years ago, Hansoh in-licensed greater China rights to a small molecule anti-viral candidate from NiKang in a $100 million deal. More details....
Stock Symbol: (HK: 3692)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.